Waldenström's Macroglobulinaemia

Burch, P. R. J.
February 1965
British Medical Journal;2/13/1965, Vol. 1 Issue 5432, p448
Academic Journal
No abstract available.


Related Articles

  • Successful Outcome of Haemodialysis-induced Pseudoporphyria after Short-term Oral N-Acetylcysteine and Switch to High-flux Technique Dialysis. Massone, Cesare; Ambros-Rudolph, Christina M.; Di Stefani, Alessandro; Mullegger, Robert R. // Acta Dermato-Venereologica;Nov2006, Vol. 86 Issue 6, p538 

    Pseudoporphyria is a blistering disease with skin fragility and shallow scarring that clinically and histopathologically closely resembles porphyria cutanea tarda. The two conditions can be distinguished by porphyrin levels that typically are elevated in porphyria cutanea tarda, but not or only...

  • Parkinsonian tremor and Waldenstrom's macroglobulinaemia. MacRury, S.; Watkins, R.; Paterson, K. R. // Journal of the Royal Society of Medicine;Apr1990, Vol. 83 Issue 4, p273 

    The article presents information on a case in which a patient with Parkinsonian tremor and was found to have Waldenstrom's macroglobulinaemia. Waldenstrom's macroglobulinaemia is a condition of plasma and lymphoid cell proliferation resulting in IgM paraproteinaemia and diffuse plasmalymphoid...

  • Work characteristics, anxiety and depression. Virtanen, Marianna // Occupational & Environmental Medicine;Feb2008, Vol. 65 Issue 2, p71 

    An abstract of the article "Externally Assessed Psychosocial Work Characteristics and Diagnoses of Anxiety and Depression," by K. Waldenström, G. Ahlberg, and P. Bergman is presented.

  • Portal hypertension in Waldenstrom's macroglobulinaemia. Brooks, Andrew P. // British Medical Journal;3/20/1976, Vol. 1 Issue 6011, p689 

    Investigates the portal hypertension in Waldenstrom's macroglobulinaemia. Descriptions of the patient; Indication of the patient's normal hepatic blood flow; Use of cyclophosphamide as treatment.

  • Bortezomib/dexamethasone.  // Reactions Weekly;May2014, Vol. 1500 Issue 1, p11 

    An abstract of the article "Necrotising fasciitis after bortezomib and dexamethasonecontaining regimen in an elderly patient of Waldenstrom macroglobulinaemia," by T. Morita and colleagues is presented.

  • Everolimus/ridaforolimus.  // Reactions Weekly;12/17/2011, Issue 1382, p20 

    The article describes 17 cases of stomatitis in patients diagnosed with carcinoma, sarcoma or Waldenstrom's macroglobulinaemia while receiving either everolimus or ridaforolimus.

  • Ibrutinib: Invasive aspergillosis: case report.  // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p175 

    The article presents a retrospective study wherein patient were treated with ibrutinib for Waldenstrom's macroglobulinaemia.

  • Rituximab.  // Reactions Weekly;1/29/2011, Issue 1336, p42 

    This article describes a case study of a 50-year-old man who developed disseminated intravascular coagulopathy (DIC) during treatment with rituximab for Waldenstrom's macroglobulinaemia.

  • Rituximab.  // Reactions Weekly;03/23/2013, Issue 1445, p32 

    The article focuses on a case study of a 47-year-old man who was treated with rituximab for Waldenstrom's macroglobulinaemia and developed progressive multifocal leukoencephalopathy (PML).

  • Rituximab.  // Reactions Weekly;12/1/2012, Issue 1430, p28 

    The article describes the case of a 70-year-old man who developed disseminated intravascular coagulopathy after receiving rituximab for the treatment of Waldenstrom macroglobulinaemia.


Other Topics